

Aumolertinib (formerly [almonertinib](#); Ameile®) is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR-TKI) that is selective for mutant EGFR over wild-type EGFR. It has been developed for the treatment of advanced EGFR mutation-positive non-small cell lung cancer (NSCLC). In the phase 3 AENEAS trial conducted in Chinese patients, aumolertinib as first-line treatment significantly prolonged progression-free survival (PFS) and duration of response (DoR) compared with gefitinib in patients with advanced EGFR mutation-positive NSCLC; overall survival (OS) data from this study are immature. In the phase 1/2 APOLLO trial, aumolertinib showed good clinical activity (based on objective response rate, PFS, DoR and OS) in Chinese patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC who had progressed on or after prior EGFR-TKI therapy. Aumolertinib has a generally manageable tolerability profile; adverse events associated with wild-type EGFR inhibition (e.g. rash and diarrhoea) were less frequent with aumolertinib than gefitinib in AENEAS. Thus, aumolertinib is a promising new option for both first-line and second-line treatment in patients with advanced EGFR mutation-positive NSCLC <sup>1)</sup>

<sup>1)</sup>  
Shirley M, Keam SJ. Aumolertinib: A Review in Non-Small Cell Lung Cancer. *Drugs*. 2022 Apr;82(5):577-584. doi: 10.1007/s40265-022-01695-2. Epub 2022 Mar 19. PMID: 35305259.

From:  
<https://neurosurgerywiki.com/wiki/> - **Neurosurgery Wiki**

Permanent link:  
<https://neurosurgerywiki.com/wiki/doku.php?id=aumolertinib>

Last update: **2024/06/07 02:56**

